Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug

Pharmacology Biochemistry and Behavior

Volumn 62, Issue 1, 1999, Pages 75-80

  Ferrari, F ^a   Ottani, A ^a   Giuliani, D ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cannabinoids; Circling; Cisplatin; Emesis; Emetine; Head shake; HU 210; Pigeons; Rats; Sedation; Vocalization

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXANABINOL; DRONABINOL; EMETINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PIGEON; PRIORITY JOURNAL; RAT; REARING; SEDATION; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ANIMALS; ANTIEMETICS; COLUMBIDAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROOMING; HYPNOTICS AND SEDATIVES; MALE; MOTOR ACTIVITY; RATS; TETRAHYDROCANNABINOL;

COLUMBA; EMESIS;

EID: 0032951515     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00114-2     Document Type: Article

References (33)

1. 9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes. J. Pharmacol. Exp.Ther. 221:1982;97-103.
2. Compton D.R., Johnson M.R., Melvin L.S., Martin B. Pharmacological profile of a series of bicyclic cannabinoid analogs. Classification as cannabimimetic agents J. Pharmacol. Exp. Ther. 260:1992;201-209.
3. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationship. Correlation of receptor binding and in vivo activities J. Pharmacol Exp. Ther. 265:1993;218-226.
4. De Fonseca F.R., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., Navarro M. Corticotropin-releasing factor (CRF) antagonist [D-PHE12, Nle21,38, CaMeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU 210 on defensive-withdrawal behavior in rats. J. Pharmacol and Exp. Ther. 276:1996;56-64.
5. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
6. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
7. 9THC on the hypothalamo-hypophyseal-adrenal axis of rats. Eur. J. Pharmacol. 12:1970;382-384.
8. Feigenbaum J.J., Richmond S.A., Weissamn Y., Mechoulam R. Inhibition of cisplatin-induced emesis in the pigeons by a non-psychotropic synthetic cannabinoid. Eur. J. Pharmacol. 169:1989;159-165.
9. 2 dopamine agonists. Physiol. Behav. 54:1993;695-700.
10. 2 agonist-induced behavioral effects in rats. Pharmacol. Biochem. Behav. 53:1996;523-530.
11. Ferrari F., Pelloni F., Giuliani D. Behavioral profile in the chicken of CQ 32-084 and CQP 201-403, two dopamine agonists. Pharmacol. Biochem. Behav. 45:1993;117-122.
12. Fishman M.W., Rosenbaum J.F., Yabusaki D.I., Carr D.B. Marijuana related anxiety. A questionnaire-based pilot study of normal and psychiatric populations Res. Commun. Subst. Abuse. 9:1988;219-226.
13. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
14. Gispen W.H., Wiegant H.M., Greven H.M., De Wied D. The induction of excessive grooming in the rat by intraventricular application of peptides derived from ACTH structure activity studies. Life Sci. 17:1975;645-650.
15. Harris L.S., Carchman R.A., Martin B.R. Evidence for the existence of specific cannabinoid binding sites. Life Sci. 22:1978;1131-1138.
16. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localisation of cannabinoid receptors in rat brain. A quantitative in vitro autoradiographic study J. Neurosci. 11:1991;563-583.
17. Jarbe T.U.C., Hiltunen A. Cannabimimetic activity of cannabinol in rats and pigeons. Neuropharmacology. 26:1987;219-228.
18. 9-tetrahydrocannabinol on hypothalamic luteinizing hormone releasing hormone and met-enkephalin content and serum levels of testosterone and corticosterone in rats. Subst. Alcohol Actions/Misuse. 4:1983;37-43.
19. Lemberger L. Potential therapeutic usefulness of marijuana. Annu. Rev. Pharmacol. Toxicol. 20:1980;151-172.
20. Levitt M. Cannabinoids as antiemetics in cancer chemotherapy. Mechoulam R. Cannabinoid as therapeutic agents. 1986;71 CRC Press, Boca Raton, FL.
21. 8-THC-dimethyleptyl in mice and dogs. Pharmacol. Biochem. Behav. 32:1989;661-666.
22. Little P.J., Compton D.R., Johnson M.R., Melvin S.L., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247:1988;1046-1051.
23. 9THC. Eur. J. Pharmacol. 41:1977;171-182.
24. 8THC). J. Pharmacol. Exp. Ther. 234:1985;784-791.
25. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253:1990;1002-1009.
26. Poddar M.K., Dewey W.L. Effect of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 214:1980;63-67.
27. 9THC and brain biogenic amines. Bradley P.B., Dhawan B.N. Drugs and central synaptic transmission. 1976;193-199 MacMillan, London.
28. 3 receptor antagonists on cisplatin-induced emesis in the pigeon. Eur. J. Pharmacol. 221:1992;343-350.
29. Tripathi H.L., Vocci F.J., Dewey W.L. Effect of cannabinoids on cholinergic systems in various regions of the mouse brain. Fed. Proc. 38:1979;590.
30. 9THC and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology (Berlin). 75:1981;294-298.
31. Weil A.T., Zinberg N.E., Nelsen J.M. Clinical psychological effects of marijuana in man. Science (Wash). 162:1968;1234-1242.
32. 3 antagonists in the pigeons. Pharmacol. Biochem. Behav. 52:1995;571-575.
33. 9-THC in normal subjects. Psychopharmacology (Berlin). 76:1982;245-250.